الفهرس | Only 14 pages are availabe for public view |
Abstract C OVID-19 is a disease caused by SARS-CoV2 infection whose course is heterogeneous and unpredictable. Most patients suffer from the mildest form, with flu-like symptoms that are often so mild that the disease can go unnoticed. Around 15% of the patients infected develop severe manifestations, including unilateral or bilateral pneumonia with acute respiratory distress syndrome (ARDS) and progressive hypoxemia that may require mechanical ventilation assistance. Systemic hyperinflammation occurs in its severest form, with multiorgan involvement (cytokine storm), lymphopenia, and marked elevation of C-reactive protein, ferritin, D-dimers, cytokines and chemokines, which can be life threatening (Manuel Serrano, 2022). Although COVID-19 is principally a respiratory disease, it also acts on the cardiovascular level and causes thrombotic events mainly in the arteries/arterioles, microcirculation and venous system. These events appear more frequently in acute infection, but they can also occur during convalescence (Manuel Serrano 2022). In conclusion, clinical significance of APAs in patients with COVID-19 pneumonia remains to be determined. Additionally, it is not yet clear how long these APAs persist and their contribution to thrombotic events in patients. Our study showed that poor outcomes were more frequent in cases with thromboembolic events risk factors, the differences statistically were significants in obesity. Also we found that poor outcomes were more frequent in cases with cytokine storm, the differences statistically were significant in thromboembolic events and deep venous thrombosis. The prognosis of COVID-19 is worse in elderly obese males or those with comorbidities such as hypertension, diabetes mellitus, atherosclerotic vascular diseases, and other chronic medical illness. The were no statistically significant differences according to fever, cough, myalgia regarding antiphspholipid antibodies findings. There was no statistically significant difference between thromboembolic events and age. |